Bamf Health

BAMF Health doses first Lu-177 BetaBart trial patient

The first patient in the Phase 1/2a study received the investigational B7-H3-targeted radiopharmaceutical therapy at BAMF Health.

RadiologySignal.com writers·May 5, 2026